Leerink steps to sidelines on Amicus amid lack of near-term catalysts

Leerink cuts Amicus Therapeutics (FOLD -2.5%) to Market Perform from Outperform.

Analyst Joseph Schwartz sees "relatively limited news flow over the near-term" and thinks the company's "aim of offering an enzyme replacement therapy that is optimized with a coformulated pharmacologic chaperone for every lysosomal storage disorder [is] compelling but may take some time."

Price target is $3.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs